While there is robust scientific backing for directing interventions towards IL-17 as an immune target to mitigate the adverse effects of targeted therapy, with the potential to be curative and serve as a favorable prognostic indicator of an anti-tumor immune response, further experimental and clinical investigations are warranted to substantiate this strategy comprehensively and stop lung cancer dissemination [80]. This evidence concerns the gene IL17A and lung carcinoma.